High Tower Advisors, LLC Akebia Therapeutics, Inc. Transaction History
High Tower Advisors, LLC
- $64.2 Billion
- Q2 2024
A detailed history of High Tower Advisors, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 88,350 shares of AKBA stock, worth $176,700. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,350
Previous 73,350
20.45%
Holding current value
$176,700
Previous $134,000
32.84%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AKBA
# of Institutions
112Shares Held
55MCall Options Held
554KPut Options Held
246K-
Black Rock Inc. New York, NY11.6MShares$23.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.28MShares$18.6 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$11.5 Million11.5% of portfolio
-
Geode Capital Management, LLC Boston, MA4.54MShares$9.07 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.06MShares$8.13 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $368M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...